Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, Ketoconazole (Ketoconazole HRA®) cannot be endorsed for use within NHS Wales for the treatment of endogenous Cushing's syndrome in adults and adolescents above the age of 12 years. |
||
|
||
Medicine details |
||
| Medicine name | ketoconazole (Ketoconazole HRA®) | |
| Formulation | 200 mg tablet | |
| Reference number | 2743 | |
| Indication | Treatment of endogenous Cushing's syndrome in adults and adolescents above the age of 12 years |
|
| Company | HRA Pharma UK & Ireland Ltd | |
| BNF chapter | Endocrine system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 26/06/2015 | |